Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

ROADMAP Consortium

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
Original languageEnglish
Pages (from-to)495-501
JournalJournal of Alzheimer's Disease
Volume67
Issue number2
DOIs
Publication statusPublished - 2019

Cite this

@article{c8ab554d842a42f188629749f27184d5,
title = "Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project",
abstract = "ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.",
author = "{ROADMAP Consortium} and John Gallacher and {de Reydet de Vulpillieres}, Frederic and Billy Amzal and Zuzanna Angehrn and Christin Bexelius and Christophe Bintener and Bouvy, {Jacoline C.} and Laura Campo and Carlos Diaz and Jean Georges and Alastair Gray and Antje Hottgenroth and Pall Jonsson and Brent Mittelstadt and Potashman, {Michele H.} and Catherine Reed and Cathie Sudlow and Robin Thompson and Antje Tockhorn-Heidenreich and Andrew Turner and {van der Lei}, Johan and Visser, {Pieter Jelle}",
year = "2019",
doi = "10.3233/JAD-180370",
language = "English",
volume = "67",
pages = "495--501",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project. / ROADMAP Consortium.

In: Journal of Alzheimer's Disease, Vol. 67, No. 2, 2019, p. 495-501.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

AU - ROADMAP Consortium

AU - Gallacher, John

AU - de Reydet de Vulpillieres, Frederic

AU - Amzal, Billy

AU - Angehrn, Zuzanna

AU - Bexelius, Christin

AU - Bintener, Christophe

AU - Bouvy, Jacoline C.

AU - Campo, Laura

AU - Diaz, Carlos

AU - Georges, Jean

AU - Gray, Alastair

AU - Hottgenroth, Antje

AU - Jonsson, Pall

AU - Mittelstadt, Brent

AU - Potashman, Michele H.

AU - Reed, Catherine

AU - Sudlow, Cathie

AU - Thompson, Robin

AU - Tockhorn-Heidenreich, Antje

AU - Turner, Andrew

AU - van der Lei, Johan

AU - Visser, Pieter Jelle

PY - 2019

Y1 - 2019

N2 - ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

AB - ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060655878&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30584137

U2 - 10.3233/JAD-180370

DO - 10.3233/JAD-180370

M3 - Article

VL - 67

SP - 495

EP - 501

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -